February 21, 2017
CureDuchenne Applauds the FDA Approval of Marathon’s EMFLAZA (deflazacort) for the Treatment of Duchenne Muscular Dystrophy
Read More
June 30, 2016
Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA
Read More
June 5, 2009
CureDuchenne Hopes FDA Will Accomodate New Class Of Muscular Dystrophy Drugs Upon Proof Of Safety
Read More
X